Nykode Therapeutics ASA - Asset Resilience Ratio

Latest as of September 2025: 6.06%

Nykode Therapeutics ASA (NYKD) has an Asset Resilience Ratio of 6.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Nkr63.93 Million

≈ $6.73 Million USD Cash + Short-term Investments

Total Assets

Nkr1.05 Billion

≈ $111.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Nykode Therapeutics ASA's Asset Resilience Ratio has changed over time. Check Nykode Therapeutics ASA strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Nykode Therapeutics ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NYKD company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr63.93 Million	6.06%
Short-term Investments	Nkr0.00	0%
Total Liquid Assets	Nkr63.93 Million	6.06%

Asset Resilience Insights

Limited Liquidity: Nykode Therapeutics ASA maintains only 6.06% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Nykode Therapeutics ASA Industry Peers by Asset Resilience Ratio

Compare Nykode Therapeutics ASA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Nykode Therapeutics ASA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	74.81%	Nkr114.82 Million ≈ $12.08 Million	Nkr153.48 Million ≈ $16.15 Million	-2.98pp
2023-12-31	77.79%	Nkr161.95 Million ≈ $17.04 Million	Nkr208.19 Million ≈ $21.91 Million	-15.15pp
2022-12-31	92.94%	Nkr205.84 Million ≈ $21.66 Million	Nkr221.48 Million ≈ $23.31 Million	+88.36pp
2021-12-31	4.58%	Nkr12.17 Million ≈ $1.28 Million	Nkr265.56 Million ≈ $27.94 Million	-6.26pp
2020-12-31	10.84%	Nkr24.94 Million ≈ $2.62 Million	Nkr230.03 Million ≈ $24.21 Million	-54.10pp
2019-12-31	64.94%	Nkr190.33 Million ≈ $20.03 Million	Nkr293.08 Million ≈ $30.84 Million	-28.71pp
2018-12-31	93.65%	Nkr143.60 Million ≈ $15.11 Million	Nkr153.34 Million ≈ $16.14 Million	-2.58pp
2017-12-31	96.23%	Nkr206.37 Million ≈ $21.72 Million	Nkr214.47 Million ≈ $22.57 Million	+86.31pp
2016-12-31	9.92%	Nkr2.47 Million ≈ $260.24K	Nkr24.93 Million ≈ $2.62 Million	--

pp = percentage points

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$110.30 Million

Nkr1.05 Billion NOK

Market Cap Rank

#18824 Global

#166 in Norway

Share Price

Nkr3.21

Change (1 day)

-5.03%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25